HIM
CSBR icon

Hillsdale Investment Management’s Champions Oncology CSBR Stock Holding History

Hillsdale Investment Management’s Portfolio CSBR Stock Details CSBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-25,100
Closed -$185K – 665
2025
Q2 		$185K Sell
25,100
-1,000
-4% -$7.06K 0.01% 464
2025
Q1 		$227K Buy
+26,100
New +$264K 0.01% 419
2020
Q3 		– Sell
-83,480
Closed -$798K – 589
2020
Q2 		$798K Buy
+83,480
New +$712K 0.07% 216

Other funds holding CSBR

BMC
Battery Management Corp Boston, Massachusetts $426M AUM 21.5% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Hillsdale Investment Management's CSBR Position: Q3 2025 in Review

Hillsdale Investment Management sold out of Champions Oncology (CSBR) in Q3 2025, closing a stake of 25,100 shares — an estimated $185K sold.

Hillsdale Investment Management first reported a position in CSBR in Q2 2020 and held it in 3 quarters. The position peaked at $798K in Q2 2020. 27 funds tracked by Wall St. Rank hold CSBR as of Q3 2025.

  • Hillsdale Investment Management reported no remaining Champions Oncology position as of Q3 2025 after selling out during the quarter.
  • Hillsdale Investment Management sold 25,100 Champions Oncology shares in Q3 2025, an estimated $185K.
  • Hillsdale Investment Management first reported a position in Champions Oncology in Q2 2020 and held it in 3 quarters.
  • Hillsdale Investment Management's Champions Oncology position peaked at $798K in Q2 2020.
  • 27 funds tracked by Wall St. Rank held Champions Oncology as of Q3 2025.

Based on Hillsdale Investment Management's 13F filing for Q3 2025, filed 10 Nov 2025.